The spike protein is the club-shaped molecule that studs the surface of coronaviruses and gives them their crown-like appearance under an electron microscope. Its job is straightforward but critical: it latches onto a human cell, triggers a shape change, and fuses the viral membrane with the cell membrane so the virus’s genetic material can slip inside. Because the spike protein is the first point of contact between virus and host, and because it sits on the outside of the virus where the immune system can see it, it became the centerpiece of nearly every COVID-19 vaccine and a major focus of antiviral drug development.
How the Spike Protein Gets the Virus Into Your Cells
Each spike protein is a trimer, meaning three identical copies wind around each other to form a single unit. Structurally, it divides into two functional halves. The top half, called S1, handles recognition and attachment. The bottom half, called S2, handles membrane fusion. S1 contains a receptor-binding domain (RBD) that physically grabs onto a protein on the surface of your cells called ACE2, which normally helps regulate blood pressure. Once the RBD locks onto ACE2, the spike protein undergoes dramatic structural rearrangements that expose S2 and allow the virus to merge with the cell’s outer membrane.1Annual Reviews. Structure, Function, and Evolution of Coronavirus Spike Proteins
The grip between the SARS-CoV-2 spike and ACE2 is tight. Binding measurements show a dissociation constant around 4.7 nanomolar, which is roughly six to seven times stronger than the binding between the original SARS virus’s spike and the same receptor.2Nature. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor That tighter grip is one reason SARS-CoV-2 spreads so efficiently between people. Interestingly, while some early variants like Alpha, Beta, and Gamma strengthened ACE2 binding even further (up to about four and a half times tighter), later variants like Delta and Omicron did not significantly increase affinity beyond the original strain.3Cell. Structural and functional basis of SARS-CoV-2 Omicron variant recognition by human ACE2 Binding strength, it turns out, is only part of the story.
The Two Cuts That Activate the Spike
The spike protein does not function straight off the viral surface. It needs to be cut by human enzymes at two specific sites, like a safety latch being released in sequence. The first cut happens at the junction between S1 and S2, performed by an enzyme called furin. This “priming” step can occur inside the infected cell before the virus is even released, so new viral particles already carry a partially activated spike. The second cut happens at a site called S2′, and it is carried out by another human enzyme, TMPRSS2, which sits on the surface of airway cells. This second cut exposes the fusion machinery in S2 and triggers the final membrane-merger step.4PubMed Central. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells
This two-step activation is one of the things that makes SARS-CoV-2 unusually effective at infecting human airways. The original SARS virus lacked the furin cleavage site entirely, meaning it relied on a single cut at the cell surface. Experiments in human lung cells showed that blocking both furin and TMPRSS2 simultaneously could completely prevent SARS-CoV-2 from entering, while blocking either one alone only partially reduced infection.5PubMed Central. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity That synergy between the two enzymes has made them attractive targets for antiviral drugs.
The Sugar Shield
The spike protein is not a naked target for the immune system. It is heavily decorated with chains of sugar molecules, a feature shared by many viral fusion proteins. These sugar molecules, called glycans, act as a shield: they physically block antibodies from reaching certain vulnerable spots on the spike’s surface. Think of it as the virus wearing camouflage made from the host’s own molecular parts, since the sugars are chemically identical to those found on human cells.6PubMed Central. Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein The glycan shield is not impenetrable, though. Certain regions of the spike, particularly the top of the RBD when it flips into an “up” position to grab ACE2, are temporarily exposed. This is precisely where many of the most effective neutralizing antibodies bind.
Before and After Fusion
The spike exists in two dramatically different shapes depending on whether it has done its job yet. Before fusing with a cell, it holds a compact, spring-loaded configuration called the prefusion state. After fusion, it collapses into a long, narrow rod called the postfusion state. High-resolution imaging of intact SARS-CoV-2 particles showed that roughly 97% of spike trimers on the virus surface were in the prefusion form, with only about 3% already in the postfusion form.7Nature. Structures and distributions of SARS-CoV-2 spike proteins on intact virions This distinction matters enormously for vaccines, because the prefusion shape is the one the immune system needs to learn to recognize. Antibodies trained against the postfusion form tend to be much less effective at preventing infection.
Researchers solved the detailed three-dimensional structure of the prefusion spike early in the pandemic, at 3.5-angstrom resolution using cryo-electron microscopy.8PubMed Central. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation That structural blueprint was published in February 2020, less than two months after the virus’s genetic sequence was shared, and it became the foundation for vaccine design worldwide.
Why Every Major Vaccine Targets the Spike
The spike protein dominates the immune response to SARS-CoV-2 in a way that few other viral proteins can match. Most neutralizing antibodies generated during natural infection target the RBD, which makes sense: blocking the RBD prevents the virus from grabbing ACE2 in the first place.9PubMed Central. Neutralizing antibodies targeting SARS-CoV-2 spike protein But the RBD is not the only target. The N-terminal domain (NTD) of S1 also attracts antibodies, including some that protect through mechanisms beyond simple neutralization, such as recruiting immune cells to destroy infected cells.10PubMed Central. A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection
T cells, the other major arm of adaptive immunity, also respond strongly to the spike. Research using peptide libraries covering the entire spike protein found robust T cell responses in people who had recovered from COVID-19.11Cell. Selective and cross-reactive T cell responses to SARS-CoV-2 When Omicron emerged with dozens of spike mutations, studies found that the mutations tended to fall in regions poorly targeted by CD4+ helper T cells, meaning most of the T cell response remained intact even against a heavily mutated variant.12Nature. T cell responses to SARS-CoV-2 spike cross-recognize Omicron This is part of why vaccinated and previously infected people generally retained protection against severe illness even when antibody-dodging variants appeared.
Engineering the Spike to Stay in the Right Shape
A raw spike protein tends to spontaneously flip from its prefusion form to the postfusion form, which is useless for training the immune system. To solve this, structural biologists introduced specific amino acid changes, called proline substitutions, at strategic points in the S2 subunit. These act like molecular pins that lock the spike in its prefusion shape. All COVID-19 vaccines authorized in the United States encode a spike with two such substitutions, known as K986P and V987P.13Nature Communications. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
Researchers later pushed this approach further with a variant called HexaPro, which contains six proline substitutions instead of two. HexaPro produces about ten times more protein than the original two-proline version and can survive heat stress, storage at room temperature, and repeated freeze-thaw cycles without losing its shape.14PubMed Central. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes For vaccine manufacturing in parts of the world without reliable cold chains, that kind of stability could be transformative.
How Variants Change the Spike Without Destroying Its Function
The spike protein is under constant evolutionary pressure from two directions that pull against each other. Mutations that help the virus dodge antibodies tend to sit in or near the RBD. But many of those same mutations weaken the spike’s grip on ACE2, which would make the virus less infectious. The virus resolves this tension through a form of molecular balancing act: compensatory mutations elsewhere in the RBD, particularly N501Y, restore ACE2 binding affinity that immune-evasion mutations take away.15Protein & Cell. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion
The practical upshot is that SARS-CoV-2 evolution does not steadily push toward tighter ACE2 binding or stronger immune evasion alone. It maintains a balance between both, which is why successive variants have not simply become universally “better” at binding. The evolutionary sweet spot appears to be a spike that binds ACE2 well enough to infect efficiently while looking different enough from past versions to partially escape existing immunity. This is also why vaccine formulations need periodic updates.
The Spike Protein Can Harm Blood Vessels Directly
Beyond its role in viral entry, the spike protein itself appears to cause damage to blood vessel cells, even without the rest of the virus attached. A growing body of lab research has shown that the S1 subunit alone can trigger inflammation and dysfunction in the endothelial cells that line blood vessels.16PubMed Central. SARS-CoV-2 and the spike protein in endotheliopathy This could help explain why severe COVID-19 so often involves blood clotting problems, even in organs where the virus itself is barely present.
In animal models, injection of S1 into mice expressing human ACE2 caused loss of a protective molecule called thrombomodulin from lung blood vessels within three days, followed by blood clot formation and tissue damage by day seven. Blocking a specific part of the complement system, a branch of innate immunity, reduced this damage substantially.17PubMed Central. SARS-CoV-2 spike protein induces lung endothelial cell dysfunction and thrombo-inflammation depending on the C3a/C3a receptor signalling Separate experiments showed that exposing small blood vessels to S1 reduced their ability to relax in response to normal signals, through a pathway involving interferon-stimulated genes.18Cardiovascular Research. Spike 1 protein of SARS-CoV-2 induces endothelial inflammation and vascular dysfunction through interferon ISG15-dependent mechanisms These findings are from controlled lab settings and animal models, so translating them directly to human disease takes caution. But they provide a plausible mechanism for the vascular complications seen in COVID-19 patients.
How Long Does Vaccine-Produced Spike Protein Stick Around
One common concern about mRNA vaccines is how long the spike protein they instruct your cells to produce remains in the body. Studies in rats given Moderna’s mRNA-1273 found that spike protein concentration in blood peaked at about 24 hours after injection, declined rapidly with a half-life of roughly 18 hours, and was undetectable in serum after three days following the first dose and after seven days following the second. The protein was found mainly at the injection site, spleen, and lymph nodes, and was not detected in the brain, heart, or lungs.19Molecular Therapy Nucleic Acids. Tissue distribution, kinetics, and metabolism of mRNA-LNP vaccines and spike protein in rats
A study of a self-amplifying mRNA vaccine in a different animal model showed a similar pattern at the injection site, where spike protein peaked around three days and became undetectable by day 15. In lymph nodes, it persisted somewhat longer, gradually declining and reaching baseline by 44 days. No spike protein was found in the spleen or blood at any time point.20Biochemistry and Biophysics Reports. Differential clearance rate of proteins encoded on a self-amplifying mRNA COVID-19 vaccine in muscle and lymph nodes The lymph node persistence is actually expected and probably helpful, since lymph nodes are where immune cells learn to recognize the spike. It does not indicate the vaccine is causing ongoing harm.
That said, in rare cases of post-vaccine myocarditis (heart inflammation), researchers detected elevated levels of free spike protein in the blood of affected individuals, averaging about 34 picograms per milliliter, whereas no free spike protein was found in vaccinated people without symptoms.21PubMed Central. Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis Whether the circulating spike caused the myocarditis or was simply a marker of an unusual immune response is still being studied. Separately, some researchers have reported detecting fragments of the S1 subunit in certain immune cells for months after vaccination in people reporting persistent post-vaccination symptoms.22PubMed Central. Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals The clinical significance of this finding is not established, and it comes from a small, specific patient group rather than the general vaccinated population.
The Search for a Pan-Coronavirus Vaccine
The RBD is the prime target for neutralizing antibodies, but it is also the region that mutates most aggressively. Researchers looking for longer-lasting protection have turned their attention to the S2 subunit, which is far more conserved across different coronaviruses. An analysis of 14 million spike protein sequences identified 17 conserved antibody-targetable regions, 11 of which are in S2, and the six most conserved of those are concentrated in a stem region near the base of the spike.23PubMed Central. Low-sugar universal mRNA vaccine against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA)
One promising strategy involves removing some of the sugar molecules that normally cover these conserved regions, making them more visible to the immune system. An experimental mRNA vaccine using this approach elicited broad immune responses, particularly from CD8+ killer T cells, against multiple SARS-CoV-2 variants and even against distantly related coronaviruses including MERS and common-cold coronaviruses.23PubMed Central. Low-sugar universal mRNA vaccine against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA) On the antibody side, researchers have identified nanobodies from alpacas that bind a highly conserved stretch of just 14 amino acids in the S2 stem helix and effectively neutralize all known SARS-CoV-2 variants plus other related bat-origin coronaviruses.24PubMed Central. Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants
These S2-targeting approaches are still in early stages. The antibodies they produce tend to be less potent on a molecule-for-molecule basis than the best RBD-targeting antibodies. But what they sacrifice in raw potency they gain in breadth: because the stem helix barely changes between variants, an immune response aimed there could theoretically protect against coronavirus strains that have not even emerged yet. This is a fundamentally different bet than updating the RBD sequence in vaccine boosters every season.
Why the Spike Drives Coronavirus Jumps Between Species
The spike protein is not only central to how SARS-CoV-2 infects humans; it is also the key molecule that determines whether a coronavirus can jump from one species to another. Changes in the spike, both in and outside the RBD, are the primary mechanism by which coronaviruses adapt to new host populations.25PubMed Central. Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission Studies of hedgehog coronaviruses, for example, have found that the spike protein evolves under positive selection pressure at specific sites in both S1 and S2, suggesting these viruses are actively acquiring features that could potentially allow cross-species transmission.26PubMed Central. Whole genome characteristics of hedgehog coronaviruses from Poland and analysis of the evolution of the Spike protein for its interspecies transmission potential
Coronaviruses also readily swap spike genes through recombination, a process where two different coronavirus strains co-infecting the same animal exchange segments of their genomes. Because the spike gene sits in a recombination-prone region, a bat coronavirus that cannot infect human cells could acquire a spike gene from a strain that can, instantly gaining the ability to bind human ACE2. This modular nature of the spike is part of why pandemic preparedness efforts now include surveillance of spike sequences in animal coronaviruses, looking for mutations that might signal increased risk of a spillover event.
Molecular Mimicry and Autoimmunity Questions
One area of active investigation is whether the spike protein shares enough similarity with human proteins to occasionally trigger the immune system to attack the body’s own tissues. Short amino acid sequences found in the spike protein sometimes match sequences in human proteins, a phenomenon called molecular mimicry. Bioinformatic screening has identified several human proteins that share short stretches with the spike, including proteins expressed in the small intestine, ovaries, and stomach.27PubMed Central. In Silico and In Vitro Evaluation of the Molecular Mimicry of the SARS-CoV-2 Spike Protein by Common Short Constituent Sequences (cSCSs) in the Human Proteome In lab testing, most of these shared sequences did not produce antibodies capable of cross-reacting with human proteins. But at least one, a six-amino-acid stretch called EPLDVL, generated antibodies that bound both the spike and a human protein called unc-80 homolog, and also reacted with several other human proteins on blot analysis.
A separate computational analysis flagged additional human proteins with spike-like regions that could theoretically be recognized by B cells, including proteins involved in cell signaling and tissue structure.28PubMed Central. SARS-CoV-2 Spike Protein and Molecular Mimicry: An Immunoinformatic Screen for Cross-Reactive Autoantigen Candidates Whether these cross-reactive antibodies actually cause disease in living people remains unclear. The finding that most shared sequences do not produce functional cross-reactive antibodies is reassuring, but the exceptions keep researchers interested. This line of investigation is relevant to both COVID-19 itself, where autoimmune phenomena have been documented, and to vaccine safety monitoring, since the vaccine also presents the spike to the immune system. The risk, if it exists, would apply to both infection and vaccination, since both expose the immune system to the same protein.
The Spike as a Diagnostic Tool
The spike protein also plays a practical role outside of therapy and vaccination. Along with the nucleocapsid protein (which sits inside the virus rather than on its surface), the spike serves as a primary target for rapid diagnostic tests. Both proteins provoke strong immune responses and can be detected using antibody-based assays.29PubMed Central. Comparative research on nucleocapsid and spike glycoprotein as the rapid immunodetection targets of COVID-19 and establishment of immunoassay strips In serological testing, which checks whether someone has been exposed to the virus, detecting anti-spike antibodies is especially useful because it can distinguish people who were vaccinated (who have anti-spike but not anti-nucleocapsid antibodies) from people who were infected (who typically have both). This distinction matters in epidemiological studies tracking population immunity and in clinical settings where knowing whether someone’s antibodies come from vaccination or infection can guide medical decisions.